bkp_duke
Well-Known Member
What makes the mRNA companies special is NOT that they build mRNA strands. It's how they get them into cells. For decades that was the hard part, "transfecting" mRNA into cells. I remember the painful electroporation days when we were ecstatic if 2% of our cells took up the mRNA strand and expressed the protein.
That should be what is viewed as the proprietary tech for mRNA companies. I just don't know if there is enough proprietary to make it a worthwhile investment, except for directed and specific use cases like vaccines.
CRSPR on the other hand is pretty ground-breaking, because it allows for pretty good (but not perfect) DNA strand editing.
That should be what is viewed as the proprietary tech for mRNA companies. I just don't know if there is enough proprietary to make it a worthwhile investment, except for directed and specific use cases like vaccines.
CRSPR on the other hand is pretty ground-breaking, because it allows for pretty good (but not perfect) DNA strand editing.
Last edited: